JAK inhibitors and COVID-19.

Area of Science:

• Immunology
• Pharmacology
• Virology

Background:

• SARS-CoV-2 infection can trigger a dysregulated immune response, leading to cytokine storms and severe COVID-19.
• Cytokines and their receptors, coupled with Janus kinases (JAKs), play a crucial role in immune regulation and antiviral defense.
• JAK inhibitors (JAKi) have demonstrated immunosuppressive effects, suggesting potential therapeutic benefits in COVID-19.

Purpose of the Study:

• To evaluate the potential of Janus kinase inhibitors (JAKi) as a therapeutic strategy for COVID-19.
• To review existing clinical data on JAKi, including baricitinib, ruxolitinib, tofacitinib, and nezulcitinib, for COVID-19 treatment.
• To discuss the emerging evidence for a class effect of JAKi in managing COVID-19 pathology.

Main Methods:

• Systematic review and meta-analysis of existing clinical trials and studies on JAK inhibitors in COVID-19.
• Analysis of the mechanism of action of JAKs and their role in SARS-CoV-2 infection.
• Examination of clinical trial data, including randomized controlled trials (RCTs) like ACTT-2 and COV-BARRIER.

Main Results:

• Several JAK inhibitors, including baricitinib, have shown potential benefits in reducing major adverse outcomes in COVID-19 patients when added to standard care.
• Baricitinib is the only JAK inhibitor recommended by the WHO for first-line treatment of severe COVID-19, supported by RCTs demonstrating reduced mortality.
• While a class effect is being explored, current convincing data primarily support baricitinib's efficacy.

Conclusions:

• JAK inhibitors represent a promising therapeutic avenue for COVID-19, particularly in mitigating severe disease progression.
• Baricitinib has established efficacy in reducing mortality in severe COVID-19, warranting its continued use and recommendation.
• Future research should focus on optimizing treatment timing and combining JAKi with antiviral therapies to enhance efficacy and manage viral replication.